These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24499322)

  • 1. How is the heart best protected in chronic dialysis patients?: Is there life in the old drugs yet? Mineralocorticoid receptor antagonism for cardiovascular prevention in chronic dialysis patients.
    Mark PB; Taylor AH; McQuarrie EP; Jardine AG
    Semin Dial; 2014; 27(4):328-32. PubMed ID: 24499322
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists.
    Suthar SD; Middleton JP
    Semin Dial; 2016; 29(1):52-61. PubMed ID: 26242304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis.
    Chen KT; Kang YN; Lin YC; Tsai IL; Chang WC; Fang TC; Wu MS; Kao CC
    Clin J Am Soc Nephrol; 2021 Jun; 16(6):916-925. PubMed ID: 34117083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid Receptor Antagonists in ESKD.
    Agarwal A; Cheung AK
    Clin J Am Soc Nephrol; 2020 Jul; 15(7):1047-1049. PubMed ID: 32269029
    [No Abstract]   [Full Text] [Related]  

  • 5. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives.
    Epstein M
    Nephrol Dial Transplant; 2003 Oct; 18(10):1984-92. PubMed ID: 13679471
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism.
    Epstein M
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):993-1003. PubMed ID: 26429402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis.
    Zhao Y; Yan B; Zhao Z; Wang S; Weng X
    Ren Fail; 2016; 38(4):589-99. PubMed ID: 26905224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms.
    Shavit L; Lifschitz MD; Epstein M
    Kidney Int; 2012 May; 81(10):955-968. PubMed ID: 22336987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid Receptor and Cardiovascular Disease.
    Buonafine M; Bonnard B; Jaisser F
    Am J Hypertens; 2018 Oct; 31(11):1165-1174. PubMed ID: 30192914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone, organ damage and dietary salt.
    Catena C; Colussi G; Sechi LA
    Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):922-8. PubMed ID: 23803228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis.
    Pitt B; Rossignol P
    J Am Coll Cardiol; 2014 Feb; 63(6):537-8. PubMed ID: 24184253
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of mineralocorticoid receptor antagonists in cardiovascular disease.
    Ferrario CM; Schiffrin EL
    Circ Res; 2015 Jan; 116(1):206-13. PubMed ID: 25552697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid receptor modulators: a patent review (2007 - 2012).
    Collin M; Niemann F; Jaisser F
    Expert Opin Ther Pat; 2014 Feb; 24(2):177-83. PubMed ID: 24215301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The aldosterone receptor--new insights?
    Fuller P
    Expert Opin Investig Drugs; 2006 Mar; 15(3):201-3. PubMed ID: 16503757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the mineralocorticoid receptor in cardiovascular disease.
    Young MJ
    Expert Opin Ther Targets; 2013 Mar; 17(3):321-31. PubMed ID: 23324064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging cardiovascular indications of mineralocorticoid receptor antagonists.
    Parviz Y; Iqbal J; Pitt B; Adlam D; Al-Mohammad A; Zannad F
    Trends Endocrinol Metab; 2015 Apr; 26(4):201-11. PubMed ID: 25707577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Rossignol P; Juillard L
    Nephrol Ther; 2017 Jun; 13(6S):6S11-6S15. PubMed ID: 29463394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a new dawn for selective mineralocorticoid receptor antagonism?
    Luther JM
    Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):456-61. PubMed ID: 24992570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
    Funder JW
    Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.